الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

نشره PR Newswire · الولايات المتحدة منذ 1 س

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Associated Press (Business)

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Business Wire

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Dow Jones Newswires

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

مشاركة

يستحق القراءة أيضًا

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows